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Summary. A retrospective survey was conducted over a
10-year period (1990–99) among 52 haematology divisions
in order to evaluate the clinical and laboratory character-
istics and outcome of patients with proven Pneumocystis
carinii pneumonia (PCP) complicating haematological dis-
eases. The study included 55 patients (18 with non-Hodg-
kin’s lymphoma, 10 with acute lymphoblastic leukaemia,
eight with acute myeloid leukaemia, five with chronic
myeloid leukaemia, four with chronic lymphocytic leuka-
emia, four with multiple myeloma, three with myelodys-
plastic syndrome, two with myelofibrosis and one with
thalassemia) who developed PCP. Among these, 18 (33%)
underwent stem cell transplantation; only two received an
oral prophylaxis with trimethroprim/sulphamethoxazole.
Twelve patients (22%) developed PCP despite protective
isolation in a laminar airflow room. The most frequent
symptoms were: fever (86%), dyspnoea (78%), non-pro-
ductive cough (71%), thoracic pain (14%) and chills (5%); a
severe hypoxaemia was present in 39 patients (71%). Chest
radiography or computerized tomography showed intersti-
tial infiltrates in 34 patients (62%), alveolar infiltrates in 12
patients (22%), and alveolar–interstitial infiltrates in nine
patients (16%). Bronchoalveolar lavage was diagnostic in
47/48 patients, induced sputum in 9/18 patients and lung
biopsy in 3/8 patients. The diagnosis was made in two
patients at autopsy. All patients except one started a specific
treatment (52 patients trimethroprim/sulphamethoxazole,
one pentamidine and one dapsone). Sixteen patients (29%)
died of PCP within 30 d of diagnosis. Multivariate analysis
showed that prolonged steroid treatment (P < 0Æ006) and a
radiological picture of diffuse lung involvement (P < 0Æ003)
were negative diagnostic factors.
Keywords: leukaemia, lymphoma, Pneumocystis carinii,
pneumonia.
Pneumocystis carinii pneumonia (PCP) is an important cause
of morbidity and mortality in immunocompromised patients
(Thomas & Limper, 1998). Although PCP is frequently
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associated with acquired immunodeficiency syndrome
(AIDS), several groups of non-AIDS immunocompromised
patients are also at risk of PCP (Smulian et al, 1993; Delmas
et al, 1995; Lee et al, 1996). These include patients with
solid tumours, those undergoing organ transplantation or
patients suffering from inflammatory conditions requiring
chronic immunosuppression with corticosteroids or cyto-
toxic agents such as purine analogues (Kovacs et al, 1984;
Yale & Limper, 1996).
In the past, the clinical characteristics and treatment
outcome of PCP in patients with haematological malig-
nancies have been widely described (Rosen et al, 1972;
Walzer et al, 1974; Ruebush et al, 19782 ; Peters et al, 1987;
Sepkowitz, 19933 ; Varthalitis et al, 1993; Arend et al, 1995).
However, at present, the use of new chemotherapies,
characterized by prolonged and deep immunosuppression,
has modified the epidemiology and outcome of this group of
patients.
On the basis of these considerations, in this retrospec-
tive analysis we reviewed, in a multicentric study, the
records of 55 patients affected by haematological malig-
nancies, who developed proven PCP between 1990 and
1999, in order to evaluate the underlying disorder, the
clinical presentation and the factors that influenced the
outcome.
PATIENTS AND METHODS
We retrospectively collected all cases of microbiologically
and/or histologically documented PCP in adult patients
(> 12 years of age) with haematological malignancies
observed between January 1990 and December 1999 in
52 GIMEMA (Gruppo Italiano Malattie EMatologiche
dell’Adulto) centres.
Diagnosis of PCP was proved, confirming the clinical and
radiological suspicion, on the basis of microbiological or
histological evidence of Pneumocystis carinii by:
• visualization of P. carinii (PC) trophoozoites (trophic form)
from sputum or bronchoalveolar (BAL) fluid, using either
a modified Wright–Giemsa or a Papanicolaou stain, and
cysts stained with toluidine blue O stain (Naimey &
Wuerker, 1995) and/or
• polymerase chain reaction (PCR), from induced sputum
and BAL fluid, using primers for the human P. carinii
mitochondrial large-subunit (mtLSU) rRNA gene (Anti-
nori et al, 1995) and/or
• immunostaining using monoclonal antibodies (mAbs) for
human P. carinii in sputum, nasopharyngeal aspirates,
BAL fluid or lung tissue obtained by transbronchial biopsy
or open lung biopsy (Kovacs et al, 1988) and/or
• histological documentation of tissue invasion by PC cysts
or trophoozoites in lung tissue obtained by transbronchial
biopsy or by open lung biopsy or at autopsy (Thomas &
Limper, 1998).
Patients not meeting these criteria were excluded from
the study.
Hospital records of patients with PCP were reviewed to
evaluate demographic data (age, sex), type and stage of
underlying haematological disease, antibiotic PC prophy-
laxis in the 30 d before diagnosis of PCP and all types of
treatment (e.g. steroids and cyclosporine).
Prophylaxis against PC was not standardized in all
centres participating in the study. An oral prophylaxis with
trimethoprim–sulphamethoxazole (TMP/SMZ) was admin-
istered twice daily two or three times a week only for
patients with lymphoprolipherative disorders (excluding
Hodgkin’s disease) and in those patients who underwent
allogeneic bone marrow transplantation.
The type of drugs employed, the total doses and duration
of treatment for PCP were also recorded. Patients had a
median follow-up of 100 d after the microbiological diag-
nosis of PCP. Mortality was judged as due to PC when death
occurred within 30 d of diagnosis as a result of respiratory
insufficiency and/or related complications. Autopsy was
carried out in nine patients only.
All patients were included in charts compiled by two of
the authors with particular experience of the subject. All
data were coded and stored in a computerized database.
Statistical methods. Definitions and end-points of the
study were agreed upon prior to chart examination. Data
were analysed by descriptive statistical methods and differ-
ences between groups were calculated using v2 test or
Fisher’s exact test if appropriate.
Factors affecting infection outcome (death versus no
death) were investigated using a stepwise backward method
and were excluded from the model when the probability was
higher than 0Æ1. Results are presented as odds ratios [OR,
with 95% confidence intervals (CI)].
The best cut-off of continuous variables (age, steroid dose,
days on steroids, neutrophil count, lymphocyte count, Po2
level) was ascertained empirically using correlation coeffi-
cients.
Probability of events was obtained using the Kaplan–
Meier method and the groups were compared by the log-
rank test. Significance was established at P < 0Æ05 (two
sided). Data were analysed using the Statistical Package for
the Social Sciences (SPSS, Chicago, IL, USA).
RESULTS
The clinical and laboratory characteristics of the 55 patients
with PCP are reported in Table I, while in Table II the
underlying diseases and the phases of their treatment are
shown.
Epidemiological data
During the study period, 55 patients with haematological
diseases were diagnosed with documented PCP.
The lack of a national register did not allow the incidence
of PCP to be calculated for each group of haematological
malignancies. However, such an evaluation was feasible for
patients with acute leukaemia admitted to the centres
involved in the study, as well as for patients undergoing
bone marrow transplantation (BMT). An infection due to PC
was demonstrated throughout the course of disease in 12
out of 2171 new cases of adult acute leukaemia (0Æ5%).
The incidence of proven PCP in transplanted patients was
calculated on the basis of the data from the Gruppo Italiano
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Trapianto di Midollo Osseo (GITMO) Registry (unpublished
data). Only 14/3741 (0Æ3%) patients were undergoing
allogeneic BMT and 5 out of 6597 (0Æ07%) submitted to
autologous BMT or autologous peripheral blood stem cell
transplantation (PBSCT) developed a PCP.
Patients’ characteristics
Patients’ age ranged between 15 and 78, with a median of
47 years, and a prevalence of males over females (38 versus
17) was observed.
The underlying haematological malignancies of patients
at the time of PCP diagnosis and the phase of treatment are
reported in Table I. Lymphoproliferative diseases represented
58% of cases (32 patients), non-Hodgkin’s lymphoma (NHL:
18 patients, 33%) and acute lymphoblastic leukaemia (ALL:
10 patients, 18%) being the most frequent malignancies
observed. One patient, affected by4 b-thalassaemia and
undergoing allogeneic bone marrow transplantation was
included in the study.
Considering the stage of the haematological diseases, in
the majority of cases, PCP (23 episodes, 42%) was
documented in patients who were in complete remission.
The latency between the diagnosis of the haematological
disease and PCP infection had a high variability and ranged
from 1 to 128 months (median 5 months).
Eighteen patients (22%) underwent BMT (allogeneic or
autologous). The median interval between transplantation
and the diagnosis of PCP was 180 d (range 10–330).
Chemotherapy and immunosuppressive treatment
Before the onset of PCP, 44/55 patients (80%) had been
treated with chemotherapy and 11/55 patients (20%) had
received immunosuppressive treatment.
Chemotherapy included cyclophosphamide in 15 patients
and cytarabine (Ara-C) in 10 patients. Only two patients
had been previously treated with purine analogues: one
patient with 2- chlorodeoxyadenosine and another with
fludarabine. Five patients were treated with cyclosporin A
(CyA) in association with steroids, while one patient
received CyA alone. Thirty-nine patients (57%) had a
history of previous treatment with corticosteroids at a
median equivalent daily dose of 50 mg (range 8–150) of
6-methyl-prednisolone for a median time of 35 d (range
3–1540), with a median total dose of 2200 mg (range
88–22 500).
At the onset of infection, 12 patients (22%) were
neutropenic (neutrophil count lower than 1 · 109/l) and
33 patients (60%) had a lymphocyte count lower than
1 · 109/l. An inversion of the CD4/CD8 ratio was observed
in 5 of 10 available cases.
Prophylaxis
Only 2 of 55 patients who developed PCP had received
prophylaxis with TMP/SMZ. The duration of prophylaxis
before the diagnosis of PCP was in one case 80 d and in one
case 270 d.
Twelve patients (22%) developed PCP despite protective
isolation in a laminar airflow room.
Clinical presentation and diagnostic procedures
The signs and symptoms related to PCP became apparent in
42 patients (76%) after discharge. In the case of 13 patients
(27%), PCP occurred during hospitalization after a median
of 38 d from admission (range 15–212).
The onset of symptoms was not uniform: in 39 cases it
was fulminate and characterized by high-grade fever and
severe hypoxaemia, while in 16 patients the presentation
was subacute with the onset of progressive dyspnoea, a non-
productive cough and a low-grade fever over several weeks.
Fever, which was present in 84% of episodes, was the most
frequent symptom.
Table I. Main clinical and laboratory features of 55 patients with
PCP observed between 1990 and 1999 in 52 centres.
Patients
Sex (males/females) 38/17
Median age (years; range) 47 (15–78)
Underlying haematological disease
NHL 18
ALL 10
AML 8
CML 5
MM 4
CLL 4
MDS 3
IMF 2
TAL 1
Environmental isolation (air laminar flow) 12/55
Kind of treatment
Chemotherapy 44/55
Immunosuppressive treatment 11/55
Transplantation
Allogeneic 12
Autologous 3
PBSC 3
Steroid treatment 39/55
No. of patients 2200 (88–22 500)
Median total dosage of methyl-
prednisolone (mg; range)
35 (3–1540)
Median treatment duration (days; range)
Previous antibiotic treatment 31/55
Median duration antibiotics (days; range) 10 (2–30)
Fever 46/55
Neutrophil count at the onset of infection
(< 1 · 109/l/> 1 · 109/l)
12/43
Lymphocyte count at the onset of infection
(< 1 · 109/l/> 2 · 109/l)
33/22
Hypoxaemia (Po2 < 70 mmHg) 39/55
Chest radiograph/CT scan 34/55
Interstitiopathy 21/55
Interstitiopathy + alveolar
Trimethoprim–sulphamethoxazole
prophylaxis
2/55
NHL, non-Hodgkin’s lymphoma; ALL, acute lymphoblastic leu-
kaemia; AML, acute myeloid leukaemia; CML, chronic myeloid
leukaemia; MM, multiple myeloma; CLL, chronic lymphocytic leu-
kaemia; MDS, myelodysplastic syndrome; IMF, idiopathic myelofi-
brosis; TALm, thalassaemia.
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Empirical broad-spectrum antibiotics (a b-lactam plus an
amino glycoside with or without glycopeptides) had been
administered in 31 cases (56%) for a median time of 10 d
(range 2–30) before the diagnosis of PCP was confirmed.
Interestingly, in nine patients (16%), a pulmonary
infection due to other pathogens was diagnosed before
diagnosis of PCP: four patients had cytomegalovirus (CMV)
pneumonia, diagnosed by positive serology; and five patients
had clinically and radiologically documented pneumonia of
unknown origin. Five of these patients (55%) died within a
median of 20 d from diagnosis of PCP (range 11–30).
Other symptoms and signs were: dyspnoea (78%), non-
productive cough and crackles (71%), thoracic pain (14%)
and chills (5%). The interval between the onset of symptoms
and PCP diagnosis ranged from 2 to 5 d.
At admission the median values of arterial blood gas
analysis of 42 patients performed at room air were: Po2
57 mmHg (range 31–93), Pco2 32 mmHg (range 23–41)
and pH 7Æ46 (range 7Æ24–7Æ52). Severe hypoxaemia (arte-
rial oxygen tension lower than 70 mmHg) was present in
39 patients (71%).
A diagnosis of PCP was made in vivo in 53 patients (96%),
while in the remaining two patients (3Æ6%) the clinical
suspicion of PCP was confirmed at autopsy only.
Standard chest radiography showed unequivocal pulmo-
nary parenchyma abnormalities in all patients. In 34
patients (75%), bilateral infiltrates were observed, while in
21 patients (25%) unilateral infiltrates were present. In
particular, a pattern of interstitial infiltrates was the most
common feature [34 patients (62%)], while radiography
showed alveolar infiltrates in 12 patients (22%) and both
interstitial and alveolar patterns in nine patients (16%).
Chest computerized tomography (CT) was performed in
20 cases, within 72 h of readiography, and confirmed the
findings shown by standard radiographs.
Nine of 18 patients studied tested positive for Pneumo-
cystis carinii on a stain of pulmonary secretions obtained
from induced sputum5 .
Bronchoscopy with BAL was performed in 48 patients
(87%) and was diagnostic for PCP in all but one patient.
This procedure was performed within 3 d of the onset of
symptomatology.
PCR analysis was performed on BAL from seven patients
only and it was positive in each case. In one case, with
negative stains, this enabled the diagnosis of PCP.
Transthoracic or transbronchial biopsy was performed on
eight patients, but histological documentation of lung
invasion by PC was documented in three patients only (37%).
The summary of the diagnostic procedures is shown in
Table III.
Treatment and outcome
In all but one patient, radiological and clinical findings
prompted empirical treatment for PCP, which was started
within 48 h of the onset of symptoms; 52 patients were
treated with high-dose i.v. TMP/SMZ at a median daily dose
Table II. Haematological malignancy and phase of treatment of 55 cases of PCP.
AML ALL NHL CML MM CLL MDS IMF TAL Total (%)
Induction/reinduction 2 1 10 – 1 1 1 – – 16 (29)
Consolidation 1 1 – – – – – – – 2 (3,6)
Maintenance 1 5 – – – 3 – 1 – 10 (18)
Autologous BMT – – 3 – – – – – – 3 (5,5)
Allogeneic BMT
Conditioning 2 1 – 1 – – – – – 12 (22)
Immunosuppression 1 1 – 4 2 – – – –
PBSCT – – 1 – 1 – – – 1 3 (5,5)
Salvage 1 1 2 – – – – – – 4 (7,2)
Immunosuppression – – 1 – – – – – – 1 (2)
None – – 1 – – – 2 1 – 4 (7,2)
Total 8 10 18 5 4 4 3 2 1 55
AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; NHL, lymphoma; CML, chronic myeloid leukaemia; MM, multiple myeloma;
CLL, chronic lymphocytic leukaemia; MDS, myelodysplastic syndrome; IMF, idiopathic myelofibrosis; TAL, thalassaemia.
Table III. Procedures that allowed diagnosis in 55 patients with proven PCP.
BAL BAL + induced sputum BAL + lung biopsy Induced sputum Autopsy
Cases 41* 3 3 6 2
*In one patient with negative stains, diagnosis was made by PCR on bronchoalveolar lavage fluid.
In one patient, diagnosis of PCP was confirmed at autopsy.
BAL, bronchoalveolar lavage.
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of 3Æ6 g (range 1Æ2–9Æ6) [3 g of sulphamethoxazole (range
1–8) and 0Æ6 g of trimethoprim (range 0Æ2–1Æ6)]. The total
median dose of i.v. TMP/SMZ administered was 43Æ2 g
(range 1Æ4–240) [36 g of sulphamethoxazole (range 1Æ2–
200) and 7Æ2 g of trimethoprim (range 0Æ2–40)], and the
median duration of therapy was 15 d (range 1–53). Patients
who improved after endovenous treatment continued oral
TMP/SMZ therapy with a median cumulative dose of 33Æ6 g
(range 7Æ7–92Æ8) [28 g of sulphamethoxazole (range 6Æ4–
77Æ3) and 5Æ6 g of trimethoprim (range 1Æ3–15Æ5)] for a
median of 14 d (range 4–29) further. The overall median
duration of treatment (i.v. plus oral) was 30 d (range 11–67).
Four patients unresponsive to the treatment with TMP/
SMZ, at a median of 12 d (range 8–30), received pentami-
dine. Three of these patients died of PCP despite pentamidine
treatment.
Two other patients intolerant of TMP/SMZ received
pentamidine or dapsone.
Corticosteroids were given to 18 patients (36Æ5%) during
anti-Pneumocystis treatment. Methyl-prednisolone (50–
80 mg/d) was added to a total median dose per patient of
770 mg (range 90–23 100) for an average of 12 d (range
1–53). Among these patients, 14 were already being treated
with methyl-prednisolone for the underlying disease.
Treatment failure occurred in 20 patients; 16 patients died
from complications related to PCP within 30 d of diagnosis
and four patients died within 60 d. A previous pulmonary
infection had been already diagnosed in four of them (three
CMV, and one clinical and radiological pneumonia), even
if this was not considered the main cause of death.
Twenty-three patients (42%) were transferred to the
intensive care unit (ICU) for respiratory failure necessitating
mechanical ventilation and 14 of them (61%) died.
Among the other 35 patients (62%) a clinical improve-
ment was observed. Six patients died within 30 d from other
causes: three patients died from the underlying haemato-
logical disease (one patient had graft-versus-host disease,
one a CMV infection and one a brain haemorrhage). All
diagnoses were confirmed at autopsy.
One patient, affected by NHL, presented a second PCP
infection 5 years after the first episode. This patient did not
receive a specific prophylaxis because she suffered from
TMP/SMZ allergy and refused any other prophylaxis. She
died 18 d after diagnosis, despite appropriate treatment.
Factors related to mortality
At multivariate analysis, absolute lymphocytopenia, hyp-
oxia at admission, presence of alveolar infiltrates at chest
radiography and a prolonged use of corticosteroids were
significantly correlated with a higher mortality from PCP
(Table IV). Other parameters such as age, sex, underlying
haematological malignancies, transplantation procedures,
hospitalization in hepafiltered rooms, chemotherapy, use of
corticosteroids and neutropenia did not influence mortality.
DISCUSSION
Pulmonary infections represent a major diagnostic and
therapeutic challenge in patients with haematological
malignancies. Usually, pneumonia is caused by Gram-
negative agents (i.e. Pseudomonas spp.) or by filamentous
fungi (i.e. Aspergillus spp. or Mucorales) (Khardori et al,
1990; Pagano et al, 1997, 1998, 1999; Patterson et al,
2000). The characteristics of PCP have been illustrated
either for patients treated with immunosuppressive treat-
ment or for those with AIDS (Rosen et al, 1972; Walzer
et al, 1974; Ruebush et al, 1978; Peters et al, 1987;
Sepkowitz, 19936 ; Varthalitis et al, 1993; Arend et al,
1995). However, the introduction of new drugs for the
treatment of haematological malignancies (i.e. purine
analogues) and the availability of innovative diagnostic
tools (i.e. PCR) that can improve the sensitivity of both
invasive and non-invasive diagnostic procedures might
have changed the epidemiology of this complication.
It has been reported that PCP has a high incidence in
preterm infants, and is especially frequent in children and
adolescents with ALL, when compared with adults. Children
and infants actually seem to be at high risk of PCP in the
context of immunosuppression caused either by the under-
lying malignancy or by pharmacological agents (Russian &
Levine, 2001). However, PCP has also been reported as a
cause of infant pneumonia in otherwise immunocompetent
infants. Serological surveys in fact indicate that the great
majority of healthy, immunocompetent infants (85%) have
a primary symptomatic Pneumocystis carinii infection before
3 years of age, suggesting that this is among the most
common infections in paediatric patients (Vargas et al,
2001). The current belief is that the primary infection in a
competent host is asymptomatic or causes an overt respi-
ratory illness, with clinical manifestations that are different
from and less severe than those known to occur in the
compromised host. PCP could represent a reactivation of a
latent infection, becoming manifest when the immunolog-
ical defences are compromised by a haematological malig-
nancy.
Before the general introduction of TMP/SMZ prophylaxis,
the incidence of PCP was more than 20% in some centres
(e.g. St Jude/Memphis and Berlin)7 , depending on the
intensity of chemotherapy and duration of steroid treatment
(Hughes et al, 1977). Later, Hughes et al (1987) demon-
strated, in a prospective randomized study of children with
acute lymphoblastic leukaemia, the same efficacy of inter-
mittent TMP/SMZ prophylaxis and continuous administra-
tion. Criteria for prophylaxis in adults without AIDS, in
particular those with haematological malignancies, have
not in contrast to the situation in children (Groll et al,
2001), been established in prospective controlled trials.
In this survey, we analysed the records of a large series of
patients with haematological malignancies and proven PCP;
these records were collected during a 10-year period from
Italian Haematological departments affiliated to the GIM-
EMA Infection programme. Our study was retrospective,
starting from the diagnosis of PCP. Owing to the lack of a
common national registry for all haematological malignan-
cies, we were not able to calculate the incidence of PCP in
each category of patients; however, we were able to
calculate the incidence of PCP in patients with acute
leukaemia and those who underwent BMT.
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As previously reported, patients with lymphoproliphera-
tive disorders and those undergoing transplantation
received intermittent prophylaxis. We have shown that
the occurrence of this complication is very rare in these
groups of patients, when compared with other opportunistic
infections such as aspergillosis or candidaemia (Pagano
et al, 1997, 1998, 1999; Patterson et al, 2000).
PCP occurs more frequently in patients with lymphopro-
liferative disorders, although it has been observed in
patients with myelodysplatic syndromes (MDS) or acute
myeloid leukaemia (AML) not receiving BMT (Peters et al,
1987; Varthalitis et al, 1993; Arend et al, 1995). Interest-
ingly, we did not observe PCP in patients with Hodgkin’s
disease (HD), in contrast to data reported by Sepkowitz
(1993). This discrepancy could be due to the lack of steroid
use in our own HD trials. Another interesting fact is the
absence of correlation between PCP and use of fludarabine
in our patients.
It has been demonstrated that purine analogues may be
associated with long-lasting T-cell lymphocytopenias, which
are considered a risk factor for the occurrence of opportu-
nistic infections caused by organisms such as Pneumocystis
Table IV. Univariate and multivariate analysis of clinical and laboratory characteristics in relation to mortality due to
PCP.
Characteristics
Death from
PCP/total (%)
Univariate analysis
P-value
Multivariate analysis
P-value
Age
< 50 (years) 12/33 (36) 1 NS
> 50 (years) 8/22 (36)
Sex
Male 12/38 (31Æ5) 0Æ3 NS
Female 8/17 (47)
Underlying disease
Myeloprolipherative 6/18 (33) 0Æ7 NS
Lymphoprolipherative 14/37 (38)
Disease stage
CR 8/24 (33) 0Æ7 NS
Other 12/31 (44)
Therapy
Chemotherapy 17/44 (39) 0Æ7 NS
Immunotherapy 3/11 (27)
Allogeneic BMT
Yes 7/12 (58) 0Æ096 NS
No 13/43 (30)
Steroids
Yes 17/40 (42Æ2) 0Æ1 NS
No 3/15 (20)
Steroids dosage
< 1000 (mg) 9/29 (31) 0Æ4 NS
> 1000 (mg) 11/26 (42)
Steroids duration
< 15 d 6/28 (21) 0Æ02 0Æ0062 (OR ¼ 2Æ8; CI ¼ 2Æ0–3Æ6)
> 15 d 14/27 (52)
Neutropenia
< 1 · 109/l 5/12 (42) 0Æ7 NS
> 1 · 109/l 15/43 (35)
Lymphopenia
< 1 · 109/l 17/35 (48Æ5) 0Æ01 0Æ003 (OR ¼ 3Æ1; CI 95% ¼ 2Æ2–4Æ0)
> 1 · 109/l 3/20 (15)
Hypoxia (mmHg)
< 70 17/39 (43Æ5) 0Æ08 0Æ0039 (OR ¼ 3Æ4; CI 95% ¼ 2Æ4–4Æ4)
> 70 3/16 (19)
Chest radiography
Interstitiopathy 8/34 (23Æ5) 0Æ01 0Æ0034 (OR ¼ 2Æ9; CI 95% ¼ 2Æ1–3Æ8)
Interstitiopathy + alveolar 12/21 (57)
Therapy
Yes, with steroids 8/22 (36) 1 NS
Yes 12/33 (36)
OR, odds ratio; CI, confidence interval; CR, complete remission.
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carinii, Listeria monocytogenes and fungi (Wijermans et al,
1993; Byrd et al, 1995). The use of purine analogues in
Italy increased after 1995 but, despite the frequent use of
these drugs in all participating centres, we observed only
two cases of PCP in patients treated with purine analogues
(2-chlorodeoxyadenosine in one case and fludarabine in the
other).
Our data are in agreement with those of Anaissie et al
(1998)9 , who demonstrated that fludarabine used alone did
not increase the incidence of PCP in a large series of CLL
patients, while a consistent number of PCP or listeriosis
cases were observed when fludarabine was used in associ-
ation with steroids. However, other authors did not attrib-
ute a critical role to steroids in the development of PCP
(Arend et al, 1995).
In our study, the diagnosis of PCP using microbiological
techniques was very efficient. However, surgical biopsy,
which generally represents one of the most useful tools for
the diagnosis of uncertain pulmonary lesions, was not as
useful. This was probably as a result of either a delay in the
procedure, which was determined by the critical condition
of the patient, or failure to reach the site of infection.
The widely held belief that PCP is a rare disease in
patients with haematological malignancies, in contrast to
patients with AIDS, may explain why oral prophylaxis
against PC with TMP/SMZ was not routinely used in most
participating centres for all cases of haematological malig-
nancies, particularly for myeloproliferative diseases. How-
ever, because of the low number of cases of PCP observed,
we would not suggest a more diffuse prophylaxis in these
patients.
Despite a timely empirical treatment with TMP/SMZ
based on clinical findings and radiological pictures, we
observed a considerable mortality rate (29%), which was
higher than that observed in patients with AIDS (10–20%),
but in agreement with other experiences (Arend et al,
1995; Yale & Limper, 1996). The combination of TMP/SMZ
with high-dose steroids did not modify the outcome.
Interestingly, in our series the specific PCP treatment was
longer than that reported by other authors in AIDS (Castro,
1998). This was probably because haematological and
other cancer patients presented, in contrast to HIV patients,
a greater degree of lung inflammation due to poorer
oxygenation and, therefore, needed prolonged treatment
(Limper et al, 1989).
Coexisting pulmonary infections (i.e. CMV) have been
frequently reported and correlated with a high mortality
rate (Wang et al, 1970; Stover et al, 1985; Peters et al,
1987). This is confirmed in our patients. In fact, 55% of
patients with PCP and a previous or concomitant bacterial
or viral pulmonary infection died within 30 d of the
diagnosis of PCP.
When analysing some parameters influencing the out-
come of our patients, hypoxia, a more extensive pulmonary
impairment and lymphopenia were found to be independent
risk factors for mortality in the multivariate analysis.
Interestingly, the outcome was not influenced either by
the cumulative or by the daily dose of steroids, whereas the
duration of steroid treatment before the onset of the
complication appeared to be correlated with a worse
prognosis.
Unfortunately, we were able to document CD4/CD8
ratio in only a few patients, and it was inverted in 50% of
them.
In conclusion, PCP represents a rare but potentially lethal
complication in patients with haematological malignancies.
It is characterized by a sudden and progressive course with
a more severe prognosis with respect to that of PCP in AIDS.
Frequently, the prompt initiation of a specific therapy with
TMP/SMZ does not change the outcome.
Prophylaxis of PCP is not widely used, but the low
number of patients who developed PCP without having a
lymphoproliferative disease or without having received an
allogeneic transplantation does not justify the use of
prophylaxis in other patient categories (i.e. AML). Further,
prospective studies on a larger number of patients are
necessary to confirm our epidemiological data.
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